Market Overview

Ambry Appoints Linh H. Le as New Chief Operating Officer


Mr. Le will be Managing Ambry's Global Business Expansion, Delivering
Precision Medicine Solutions to Untapped Markets

Ambry Genetics Corporation (Ambry), a leader in clinical genetic
diagnostics, announced today that Linh H. Le will serve as Ambry's new
Chief Operating Officer (COO). Linh's primary role will be to develop a
scalable operational strategy as Ambry expands its reach globally,
following a successful acquisition by Konica Minolta.

This press release features multimedia. View the full release here:

Mr. Linh Le (Photo: Business Wire)

Mr. Linh Le (Photo: Business Wire)

Konica Minolta closed its acquisition of Ambry in late October, with a
mission to combine the companies' technologies into a global solution
for precision medicine. Mr. Le will contribute heavily towards ensuring
Ambry's operations are well-prepared to achieve that goal.

Linh brings more than 25 years of work experience, stemming from several
industry sectors including medical devices, biopharmaceutical,
entertainment and management advisory services. Mr. Le spent the last 14
years in the healthcare industry overseeing financial operations at
Medtronic's Diabetes Intensive Insulin Business Unit. Prior to that,
Linh held leadership roles at the Walt Disney Company,
PricewaterhouseCoopers, Twentieth Century Fox and KPMG.

"As we grow our reach globally, we are confident that Linh's
international experience will be instrumental in designing a strategic
expansion into new markets," says Ambry CEO Dr. Aaron Elliott. "Linh's
vision and experience will provide the strong foundation we need."

In his role as Chief Operating Officer, Mr. Le will provide leadership,
management and guidance to the senior leadership team on all matters
relating to the financial strategy and operations of the organization.

"We are pleased to have Mr. Le join the team, bringing with him his
vision and operational expertise," said Kiyotaka Fujii, President of
Global Healthcare, Konica Minolta. "By overseeing the revenue cycle from
beginning to end, Linh will help Ambry become a strong leader in
precision medicine development while remaining financially successful."

"This is an exciting time to join Ambry," says Mr. Le. "I am humbled by
the opportunity to work with an organization with admirable core values
and a solid mission statement. Following in the footsteps of Konica
Minolta, our aim is to achieve operational excellence on a global scale.
Together, we will revolutionize healthcare in a meaningful way by
improving the quality of life for our patients through precision

About Ambry

Ambry Genetics is both College of American Pathologists (CAP)-accredited
and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry
is an established leader in clinical genetic diagnostics and software
solutions, combining both to offer the most comprehensive testing menu
in the industry. Ambry has established a reputation for sharing data
while safeguarding patient privacy, unparalleled service, and
responsibly applying new technologies to the clinical molecular
diagnostics market. For more information about Ambry Genetics, visit

View Comments and Join the Discussion!